Amarin Technologies S.A. has no direct marketing force and pursues a strategy of out-licensing for its products to corporate partners. The Company also enters into strategic alliances that provide for the development of pharmaceutical products in exchange of technology funding, milestone payments, royalties and other financial arrangements.

The Company business opportunities are, among others, focused on four main areas:

• Finding new partners for the existing projects or,
• Developing new products on request or,
• Developing new early stage projects to be offered to pre-determined and selected candidates or,
• Technology Transfer Agreements.

Amarin is presently carrying on discussions with different companies in order to develop or license different kinds of products under the Amarin patented technology.

Among the existing commercial relationships, we can disclose those which cover our products with Merck KGaA (Germany), Zydus Cadila (India), Sandoz (Austria), Genericon Pharma Gesellschaft m.b.H. (Austria)Helm Pharmaceuticals (Germany), Laboratorios Beta S.A. (Argentina), Wyeth (U.S.A.), Eurofarma (Brazil), Unimed (Korea), Ranbaxy (India), Mega Pharma (Uruguay), TAD Pharma GmbH (Germany), Riemser Arzneimittel AgG (Germany), Gedeon RichterLtd (Hungary), Esparma GmbH (Germany), Biogaran (France), Mibe GmbH (Germany), Krewel Meuselbach GmbH (Germany), Generis Farmaceutica S.A.(Portugal), (Kwizda Pharma GmbH (Austria), Laboratorios Cinfa S.A.(Spain), Laboratorios Normon S.A. (Spain), Kern Pharma S.A. (Spain), Heumann Pharma GmbH (Germany), Adcock Ingram Healthcare (Pty) Ltd. (South Africa), Algol Pharma OY (Finland),Gry Pharma GmbH (Germany), Drossapharma AG (Switzerland),P N Gerolymatos S.A. (Greece), Demos S.A. (Greece), Aliud Pharma GmbH (Germany), BioPro Pharmaceuticals Inc (USA).